![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
lauraanne_gilmanClinton’s Foundation Brokers AIDS Deal
By ANAND GIRIDHARADAS
Published: November 30, 2006
MUMBAI, Nov. 30 — The cost of treating children infected with H.I.V. and AIDS is poised to plummet next year, under a deal announced today between two Indian drugmakers and former President Bill Clinton’s foundation.
Cipla and Ranbaxy Laboratories agreed to make 19 different anti-retroviral drugs designed for children available at an average price of 16 cents a day, or $60 a year, which is about 45 percent lower than the lowest current price, the Clinton Foundation said in a statement.
Because not everyone has access to the current lowest price, the plan will actually translate into a four- to six-fold cost reduction for many children, said Stephen Lewis, the United Nations special envoy for H.I.V. and AIDS in Africa.
The prices will be available to 62 developing countries and will lead to the treatment of an additional 100,000 people in 2007, the statement said.
read more here via the New York Times
(they were racing the clock, according to the article, because laws are about to change in India that would have made this deal impossible in a few years. While I'm all for patent protection, and all for pharmecutical copies recouping the not-inconsiderable costs of research and development.... I'm still cheering this like crazy.)
By ANAND GIRIDHARADAS
Published: November 30, 2006
MUMBAI, Nov. 30 — The cost of treating children infected with H.I.V. and AIDS is poised to plummet next year, under a deal announced today between two Indian drugmakers and former President Bill Clinton’s foundation.
Cipla and Ranbaxy Laboratories agreed to make 19 different anti-retroviral drugs designed for children available at an average price of 16 cents a day, or $60 a year, which is about 45 percent lower than the lowest current price, the Clinton Foundation said in a statement.
Because not everyone has access to the current lowest price, the plan will actually translate into a four- to six-fold cost reduction for many children, said Stephen Lewis, the United Nations special envoy for H.I.V. and AIDS in Africa.
The prices will be available to 62 developing countries and will lead to the treatment of an additional 100,000 people in 2007, the statement said.
read more here via the New York Times
(they were racing the clock, according to the article, because laws are about to change in India that would have made this deal impossible in a few years. While I'm all for patent protection, and all for pharmecutical copies recouping the not-inconsiderable costs of research and development.... I'm still cheering this like crazy.)
